Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...
4hon MSN
Health care roundup: Market talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
A key number for Merck in the coming years is $70 billion. This is the mid-2030s revenue opportunity from potential new ...
Merck Still Wants to "Grow Through Keytruda," Expects $70B in Revenue From New Programs by Mid-2030s
Two antibody-drug conjugates are among 10 programs that the company expects to fuel its growth, the company said.
Merck (NYSE:MRK) says it now sees up to $70 billion in new revenue opportunities by the mid-2030s, as it works to offset the ...
Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the ...
MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn ...
Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback